Serina Therapeutics Stock Performance
| SER Stock | 2.47 0.37 13.03% |
The entity has a beta of 1.47, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Serina Therapeutics will likely underperform. At this point, Serina Therapeutics has a negative expected return of -0.53%. Please make sure to validate Serina Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Serina Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Serina Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain relatively invariable which may send shares a bit higher in March 2026. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (13.03) | Five Day Return (28.41) | Year To Date Return 18.75 | Ten Year Return (97.45) | All Time Return (97.45) |
Last Split Factor 28:1000 | Last Split Date 2024-03-15 |
1 | Acquisition by Moreadith Randall of 6500 shares of Serina Therapeutics at 0.06 subject to Rule 16b-3 | 11/10/2025 |
2 | Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights | 11/13/2025 |
3 | Disposition of 535 shares by Moreadith Randall of Serina Therapeutics at 3.935 subject to Rule 16b-3 | 11/24/2025 |
4 | Disposition of 5965 shares by Moreadith Randall of Serina Therapeutics at 3.9001 subject to Rule 16b-3 | 11/25/2025 |
5 | Disposition of 5000 shares by Moreadith Randall of Serina Therapeutics at 3.5246 subject to Rule 16b-3 | 12/03/2025 |
6 | Disposition of 600 shares by Moreadith Randall of Serina Therapeutics at 3.3133 subject to Rule 16b-3 | 12/09/2025 |
7 | Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry | 12/11/2025 |
8 | Disposition of 3227 shares by Moreadith Randall of Serina Therapeutics at 2.9631 subject to Rule 16b-3 | 12/16/2025 |
9 | Disposition of 5673 shares by Moreadith Randall of Serina Therapeutics at 2.6737 subject to Rule 16b-3 | 12/22/2025 |
10 | Disposition of 13000 shares by Moreadith Randall of Serina Therapeutics at 2.6887 subject to Rule 16b-3 | 01/08/2026 |
11 | Acquisition by Moreadith Randall of 4196 shares of Serina Therapeutics at 0.06 subject to Rule 16b-3 | 01/09/2026 |
12 | Disposition of 6500 shares by Moreadith Randall of Serina Therapeutics at 0.06 subject to Rule 16b-3 | 01/12/2026 |
13 | Disposition of 5416 shares by Moreadith Randall of Serina Therapeutics at 2.5 subject to Rule 16b-3 | 01/13/2026 |
14 | Disposition of 1084 shares by Moreadith Randall of Serina Therapeutics at 2.5031 subject to Rule 16b-3 | 01/14/2026 |
15 | Disposition of 2000 shares by Moreadith Randall of Serina Therapeutics at 3.07 subject to Rule 16b-3 | 01/20/2026 |
16 | Disposition of 2000 shares by Moreadith Randall of Serina Therapeutics at 3.0 subject to Rule 16b-3 | 01/21/2026 |
17 | Disposition of 2500 shares by Moreadith Randall of Serina Therapeutics at 2.95 subject to Rule 16b-3 | 01/22/2026 |
18 | Disposition of 6500 shares by Moreadith Randall of Serina Therapeutics at 3.7541 subject to Rule 16b-3 | 01/26/2026 |
19 | Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinsons disease | 01/28/2026 |
20 | Disposition of 6500 shares by Moreadith Randall of Serina Therapeutics at 4.9672 subject to Rule 16b-3 | 01/30/2026 |
21 | Disposition of 6500 shares by Moreadith Randall of Serina Therapeutics at 3.0277 subject to Rule 16b-3 | 02/02/2026 |
22 | All Ordinaries Mining Segment Reflects Alligator Energy Corporate Developments | 02/03/2026 |
23 | Samphire Project Update Positioned Within All Ordinaries Mining Framework | 02/05/2026 |
| Begin Period Cash Flow | 7.6 M | |
| Total Cashflows From Investing Activities | -22 K |
Serina Therapeutics Relative Risk vs. Return Landscape
If you would invest 399.00 in Serina Therapeutics on November 8, 2025 and sell it today you would lose (152.00) from holding Serina Therapeutics or give up 38.1% of portfolio value over 90 days. Serina Therapeutics is generating negative expected returns assuming volatility of 7.532% on return distribution over 90 days investment horizon. In other words, 67% of stocks are less volatile than Serina, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Serina Therapeutics Target Price Odds to finish over Current Price
The tendency of Serina Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.47 | 90 days | 2.47 | about 84.13 |
Based on a normal probability distribution, the odds of Serina Therapeutics to move above the current price in 90 days from now is about 84.13 (This Serina Therapeutics probability density function shows the probability of Serina Stock to fall within a particular range of prices over 90 days) .
Serina Therapeutics Price Density |
| Price |
Predictive Modules for Serina Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Serina Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Serina Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Serina Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Serina Therapeutics is not an exception. The market had few large corrections towards the Serina Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Serina Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Serina Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.87 | |
β | Beta against Dow Jones | 1.47 | |
σ | Overall volatility | 0.72 | |
Ir | Information ratio | -0.12 |
Serina Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Serina Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Serina Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Serina Therapeutics generated a negative expected return over the last 90 days | |
| Serina Therapeutics has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 56 K. Reported Net Loss for the year was (11.21 M) with loss before taxes, overhead, and interest of (12 M). | |
| Serina Therapeutics has about 3.67 M in cash with (17.14 M) of positive cash flow from operations. | |
| Roughly 47.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from kalkinemedia.com: Samphire Project Update Positioned Within All Ordinaries Mining Framework |
Serina Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Serina Stock often depends not only on the future outlook of the current and potential Serina Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Serina Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 7.4 M | |
| Cash And Short Term Investments | 3.7 M |
Serina Therapeutics Fundamentals Growth
Serina Stock prices reflect investors' perceptions of the future prospects and financial health of Serina Therapeutics, and Serina Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Serina Stock performance.
| Return On Equity | -4.85 | ||||
| Return On Asset | -1.38 | ||||
| Operating Margin | (188.69) % | ||||
| Current Valuation | 26.97 M | ||||
| Shares Outstanding | 10.79 M | ||||
| Price To Book | 29.88 X | ||||
| Price To Sales | 264.06 X | ||||
| Revenue | 56 K | ||||
| Gross Profit | (12 M) | ||||
| EBITDA | (10.49 M) | ||||
| Net Income | (11.21 M) | ||||
| Cash And Equivalents | 3.67 M | ||||
| Total Debt | 268 K | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (17.14 M) | ||||
| Earnings Per Share | (1.92) X | ||||
| Market Capitalization | 30.63 M | ||||
| Total Asset | 6.72 M | ||||
| Retained Earnings | (44.32 M) | ||||
| Working Capital | 3.31 M | ||||
About Serina Therapeutics Performance
Assessing Serina Therapeutics' fundamental ratios provides investors with valuable insights into Serina Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Serina Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.49) | (1.57) | |
| Return On Capital Employed | (4.50) | (4.27) | |
| Return On Assets | (1.49) | (1.57) | |
| Return On Equity | (19.99) | (18.99) |
Things to note about Serina Therapeutics performance evaluation
Checking the ongoing alerts about Serina Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Serina Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Serina Therapeutics generated a negative expected return over the last 90 days | |
| Serina Therapeutics has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 56 K. Reported Net Loss for the year was (11.21 M) with loss before taxes, overhead, and interest of (12 M). | |
| Serina Therapeutics has about 3.67 M in cash with (17.14 M) of positive cash flow from operations. | |
| Roughly 47.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from kalkinemedia.com: Samphire Project Update Positioned Within All Ordinaries Mining Framework |
- Analyzing Serina Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Serina Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Serina Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Serina Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Serina Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Serina Therapeutics' stock. These opinions can provide insight into Serina Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.